Third clinical test on SK drug starts

After proving its safety and efficacy in the first round, SK Chemicals announced Sunday that its business partner CSL Limited, a biopharmaceutical company headquartered in Melbourne, Australia, has started Phase III clinical trial for “NBP601,” a drug for treatment of hemophilia A exclusively developed by its research and development center.

In 2009, SK signed an agreement with CSL to export...